The gene expressions of potential EGFR-TKI-resistance modulators were analyzed in the wild type-EGFR NSCLC cell lines H358-P and H2170-P and compared to corresponding Erlotinib-resistant H358-ER and H2170-ER cell lines. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.